Helix Medical Opens Medical Device Manufacturing Operations in Europe

Helix Medical Opens Medical Device Manufacturing Operations in Europe

February 16, 2010

Carpinteria, CA -- Helix Medical, LLC, a global manufacturer for the medical device, health care, pharmaceutical, IVD, and biotech industries, announces the opening of Helix Medical Europe KG.

Helix Medical Europe begins production this month at their newly built, state-of-the-art, 55,000 square foot facility located in Kaiserslautern, Germany. Initial manufacturing services will include custom molding of silicone components for medical devices. Within the next 12 months they plan to add custom molding of thermoplastics and TPE's, multi-component molding, as well as close tolerance single and multi-lumen extrusion of silicone and TPE's.

"Our objective is to move our operations closer to our customers so that we can serve their manufacturing and distribution needs on a global level," said Dr. Jorg Schneewind, President & CEO of Helix Medical, LLC. "The fact that we were able to build on the infrastructure of an existing facility owned by our parent company, Freudenberg, created a tremendous opportunity or European expansion."

For more information on Helix Medical Europe KG please contact Thomas M. Vassallo, EVP Global Business Development at (805)684-3304.

About Helix Medical

Helix Medical, LLC is a subsidiary of Freudenberg-NOK General Partnership and its operations comprise the Health Care Products division of Freudenberg-NOK. Founded in 1984, Helix Medical is a global custom manufacturer for the medical device, health care, pharmaceutical, IVD and biotech industries. Manufacturing capabilities include silicone molding (LSR, HCR), thermoplastic molding, close tolerance multi-lumen extrusion, assembly, and packaging. Headquartered in Carpinteria, CA, Helix Medical operates an FDA-registered medical device facility, certified ISO 13485 with ISO 14644 Class 7 & 8 cleanrooms. Additional medical manufacturing operations are located in Baldwin Park, CA; Gloucester, MA; Shenzhen, China; and Kaiserslautern, Germany. www.helixmedical.com

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.